JP2009215299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009215299A5 JP2009215299A5 JP2009092074A JP2009092074A JP2009215299A5 JP 2009215299 A5 JP2009215299 A5 JP 2009215299A5 JP 2009092074 A JP2009092074 A JP 2009092074A JP 2009092074 A JP2009092074 A JP 2009092074A JP 2009215299 A5 JP2009215299 A5 JP 2009215299A5
- Authority
- JP
- Japan
- Prior art keywords
- igf
- composition
- binding
- deoxycholamine
- gluconamidopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 42
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 41
- 238000000034 method Methods 0.000 claims 40
- 239000000203 mixture Substances 0.000 claims 17
- 239000000556 agonist Substances 0.000 claims 12
- 239000013078 crystal Substances 0.000 claims 8
- 238000002425 crystallisation Methods 0.000 claims 6
- 230000008025 crystallization Effects 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 5
- 239000001509 sodium citrate Substances 0.000 claims 5
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims 4
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims 4
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 claims 4
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 238000009792 diffusion process Methods 0.000 claims 3
- 208000037824 growth disorder Diseases 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 230000010807 negative regulation of binding Effects 0.000 claims 3
- 230000001376 precipitating effect Effects 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 238000012286 ELISA Assay Methods 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- SAMYCKUDTNLASP-UHFFFAOYSA-N hexane-2,2-diol Chemical compound CCCCC(C)(O)O SAMYCKUDTNLASP-UHFFFAOYSA-N 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 208000018360 neuromuscular disease Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 241001515965 unidentified phage Species 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 206010007733 Catabolic state Diseases 0.000 claims 1
- 102100038796 E3 ubiquitin-protein ligase TRIM13 Human genes 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 101000664589 Homo sapiens E3 ubiquitin-protein ligase TRIM13 Proteins 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 208000006302 Laron syndrome Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000006227 SHORT syndrome Diseases 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000011032 Werner Syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 208000016253 exhaustion Diseases 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 102000044162 human IGF1 Human genes 0.000 claims 1
- 230000003345 hyperglycaemic effect Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 claims 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26797701P | 2001-02-09 | 2001-02-09 | |
| US28707201P | 2001-04-27 | 2001-04-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002564956A Division JP4489352B2 (ja) | 2001-02-09 | 2002-02-01 | Ｉｇｆ−１の結晶化 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009215299A JP2009215299A (ja) | 2009-09-24 |
| JP2009215299A5 true JP2009215299A5 (enExample) | 2010-05-20 |
Family
ID=26952796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002564956A Expired - Fee Related JP4489352B2 (ja) | 2001-02-09 | 2002-02-01 | Ｉｇｆ−１の結晶化 |
| JP2009092074A Withdrawn JP2009215299A (ja) | 2001-02-09 | 2009-04-06 | Ｉｇｆ−１の結晶化 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002564956A Expired - Fee Related JP4489352B2 (ja) | 2001-02-09 | 2002-02-01 | Ｉｇｆ−１の結晶化 |
Country Status (19)
| Country | Link |
|---|---|
| US (8) | US7084240B2 (enExample) |
| EP (3) | EP1801120A1 (enExample) |
| JP (2) | JP4489352B2 (enExample) |
| KR (1) | KR100872613B1 (enExample) |
| CN (1) | CN100439397C (enExample) |
| AT (2) | ATE439378T1 (enExample) |
| AU (1) | AU2002255508B2 (enExample) |
| BR (1) | BR0207422A (enExample) |
| CA (1) | CA2431033A1 (enExample) |
| DE (3) | DE60217066D1 (enExample) |
| DK (2) | DK1772464T3 (enExample) |
| ES (2) | ES2278020T3 (enExample) |
| HU (1) | HUP0500733A3 (enExample) |
| IL (2) | IL156435A0 (enExample) |
| MX (1) | MXPA03007042A (enExample) |
| NZ (3) | NZ526672A (enExample) |
| PL (1) | PL374181A1 (enExample) |
| WO (1) | WO2002064627A2 (enExample) |
| ZA (1) | ZA200304900B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1401476A4 (en) * | 2001-03-14 | 2006-03-08 | Genentech Inc | IGF ANTAGONIST PEPTIDES |
| US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| DE60224419D1 (de) * | 2001-09-18 | 2008-02-14 | Bioexpertise Llc | Von igf-bindungsprotein stammendes peptid |
| US6914049B2 (en) * | 2001-09-18 | 2005-07-05 | Bioexpertise, Llc | IGF-binding protein-derived peptide or small molecule |
| CA2565308A1 (en) * | 2003-05-06 | 2004-11-25 | New Century Pharmaceuticals | Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties |
| WO2005041895A2 (en) * | 2003-11-03 | 2005-05-12 | New Century Pharmaceuticals, Inc. | Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties |
| ES2348303T3 (es) | 2003-12-08 | 2010-12-02 | Cpex Pharmaceuticals, Inc. | Composiciones farmacauticas y procedimientos de tratamiento con insulina. |
| WO2005108424A1 (en) * | 2004-05-06 | 2005-11-17 | Genentech, Inc. | Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use |
| US20060003931A1 (en) * | 2004-05-06 | 2006-01-05 | Genentech, Inc. | Crystal structure of the hepatocyte growth factor and methods of use |
| WO2006014673A2 (en) * | 2004-07-19 | 2006-02-09 | Nobex Corporation | Insulin-oligomer conjugates, formulations and uses thereof |
| WO2006039622A2 (en) * | 2004-10-01 | 2006-04-13 | Invitrogen Corporation | Feeding buffers, systems, and methods for in vitro synthesis of biomolecules |
| US7556776B2 (en) * | 2005-09-08 | 2009-07-07 | President And Fellows Of Harvard College | Microfluidic manipulation of fluids and reactions |
| US7994127B2 (en) * | 2007-06-08 | 2011-08-09 | Massachusetts Institute Of Technology | Treatment of rett syndrome |
| WO2009026172A2 (en) * | 2007-08-17 | 2009-02-26 | The Regents Of The University Of California | New approach for designing diabetes drugs |
| CN101139391B (zh) * | 2007-08-21 | 2012-07-25 | 陈志南 | Cd147胞外区晶体结构及应用 |
| WO2009134395A2 (en) | 2008-04-28 | 2009-11-05 | President And Fellows Of Harvard College | Microfluidic device for storage and well-defined arrangement of droplets |
| WO2011011071A2 (en) * | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) |
| JP5571186B2 (ja) * | 2009-07-22 | 2014-08-13 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | ５９位にアミノ酸置換を有するインスリン様増殖因子−１（ｉｇｆ−１）の類似体 |
| WO2011047204A1 (en) * | 2009-10-14 | 2011-04-21 | Mount Sinai School Of Medicine | Method of treating memory disorders and enhancing memory using igf-ii compounds |
| US20150119394A1 (en) * | 2012-03-28 | 2015-04-30 | Merck Sharp & Dohme Corp. | Insulin-Like Growth Factor-1 Receptor Inhibitors |
| KR101711584B1 (ko) * | 2012-12-18 | 2017-03-02 | 재단법인 의약바이오컨버젼스연구단 | 변형된 eprs 단백질의 결정 구조 및 이의 결정화 방법 |
| US10279013B2 (en) | 2013-12-19 | 2019-05-07 | Puretein Bioscience Llc | Methods for treating an animal |
| CA3153776A1 (en) | 2019-09-09 | 2021-03-18 | The University Of Chicago | Combination therapy for the treatment of migraines |
| US20240050455A1 (en) * | 2020-06-01 | 2024-02-15 | Loma Linda University Health | Methods of treatment of a cytokine storm |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US589867A (en) * | 1897-09-14 | Clothes-line hanger | ||
| US577276A (en) * | 1897-02-16 | Quarter-saver iv | ||
| US4672108A (en) * | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
| DE3327709A1 (de) * | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
| WO1987001038A1 (en) * | 1985-08-22 | 1987-02-26 | Commonwealth Scientific And Industrial Research Or | Peptide analogues of mammalian insulin-like growth factor-1 |
| DE3717370A1 (de) * | 1987-05-22 | 1988-12-01 | Hoechst Ag | Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus |
| US4833233A (en) * | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
| SE8703625D0 (sv) | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
| US4876242A (en) * | 1987-09-21 | 1989-10-24 | Merck & Co., Inc. | Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast |
| US5470828A (en) * | 1987-12-24 | 1995-11-28 | Gropep Pty. Ltd. | Peptide analogs of insulin-like growth factor II |
| US5164370A (en) * | 1987-12-24 | 1992-11-17 | Gropep Pty. Ltd. | Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2) |
| US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
| EP0327503B1 (en) * | 1988-02-05 | 1993-03-10 | Ciba-Geigy Ag | Use of igf i in the manufacture of a medicament for the treatment of renal diseases |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| GB8920381D0 (en) | 1989-09-08 | 1989-10-25 | Greater Glasgow Health Board | Treatment of insulin-resistant diabetes |
| US5028224A (en) * | 1990-01-09 | 1991-07-02 | Kimberly-Clark Corporation | Apparatus for intermittently depositing particulate material in a substrate |
| US5681814A (en) | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US5374620A (en) * | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
| SE9100099D0 (sv) | 1991-01-11 | 1991-01-11 | Kabi Pharmacia Ab | Use of growth factor |
| US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
| US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
| DE69218948T2 (de) * | 1991-08-01 | 1997-07-31 | Auckland Uniservices Ltd | IGF-I zur Verbesserung der neuronale Lage |
| US5126314A (en) * | 1991-09-06 | 1992-06-30 | Eastman Kodak Company | Mixture of dyes for black dye donor for thermal color proofing |
| US6310040B1 (en) | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
| JPH07508025A (ja) | 1992-05-08 | 1995-09-07 | トーマス・ジェファーソン・ユニバーシティ | インスリン様増殖因子（ｉｇｆ−１）類似体 |
| SE9201573D0 (sv) | 1992-05-19 | 1992-05-19 | Kabi Pharmacia Ab | Use of igf-1 |
| JPH08507916A (ja) | 1992-06-09 | 1996-08-27 | カイロン コーポレイション | Ｍ−ｃｓｆの結晶化 |
| DE69327402T2 (de) | 1992-06-12 | 2000-05-04 | Albert Einstein College Of Medicine Of Yeshiva University, Bronx | Vorbeugung und behandlung der peripheren neuropathie |
| GB9217696D0 (en) | 1992-08-20 | 1992-09-30 | Agricultural & Food Res | Use of specific binding molecules |
| US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
| JPH08500123A (ja) | 1993-01-25 | 1996-01-09 | ザ ベス イスラエル ホスピタル アソシエイション | Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法 |
| DK72793D0 (da) | 1993-06-21 | 1993-06-21 | Novo Nordisk As | Nyt produkt |
| US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
| US5407810A (en) | 1993-08-20 | 1995-04-18 | Genentech, Inc. | Aqueous multiple-phase isolation of polypeptide |
| US5504188A (en) * | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
| US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| SE9402370D0 (sv) | 1994-07-04 | 1994-07-04 | Pharmacia Ab | Use of IGF-I |
| US5597893A (en) * | 1994-10-31 | 1997-01-28 | Eli Lilly And Company | Preparation of stable insulin analog crystals |
| YU18596A (sh) * | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogne formulacije monomernog insulina |
| SE9501472D0 (sv) | 1995-04-21 | 1995-04-21 | Pharmacia Ab | Truncated IGF-I |
| DK0833847T3 (da) | 1995-06-22 | 2003-12-29 | Biogen Inc | Krystaller af fregmenter af CD40-ligand og deres anvendelse |
| US5948751A (en) * | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
| JP3417230B2 (ja) * | 1996-09-25 | 2003-06-16 | 信越化学工業株式会社 | 型取り母型用光硬化性液状シリコーンゴム組成物 |
| US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| US5898028A (en) * | 1997-03-20 | 1999-04-27 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
| US6121416A (en) * | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| CA2294833A1 (en) | 1997-07-03 | 1999-01-14 | Smithkline Beecham Corporation | Crystal structures of anti-factor ix fab fragments and methods of use for peptidomimetic design |
| US5876242A (en) * | 1997-07-21 | 1999-03-02 | Williams; Hugh D. | Remote battery extension apparatus |
| NZ506091A (en) | 1998-01-21 | 2003-07-25 | Brigham & Womens Hospital | Circulating insulin-like growth factor-i and prostate cancer risk |
| AU6515499A (en) | 1998-10-16 | 2000-05-08 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
| EP1383793B1 (en) | 2000-03-29 | 2011-10-19 | DGI BioTechnologies, L.L.C. | Insulin and igf-1 receptor agonists and antagonists |
| WO2002098914A2 (en) | 2001-06-07 | 2002-12-12 | F. Hoffmann-La Roche Ag | Mutants of igf binding proteins and methods of production of antagonists thereof |
| US20040137518A1 (en) * | 2002-01-31 | 2004-07-15 | Lambert Millard Hurst | CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME |
| JP3680801B2 (ja) * | 2002-02-27 | 2005-08-10 | 株式会社デンソー | 回転電機の巻線接合方法 |
-
2002
- 2002-02-01 PL PL02374181A patent/PL374181A1/xx not_active Application Discontinuation
- 2002-02-01 AT AT06026832T patent/ATE439378T1/de active
- 2002-02-01 NZ NZ526672A patent/NZ526672A/en not_active IP Right Cessation
- 2002-02-01 DE DE60217066A patent/DE60217066D1/de not_active Expired - Lifetime
- 2002-02-01 HU HU0500733A patent/HUP0500733A3/hu unknown
- 2002-02-01 MX MXPA03007042A patent/MXPA03007042A/es active IP Right Grant
- 2002-02-01 DK DK06026832T patent/DK1772464T3/da active
- 2002-02-01 ES ES02724908T patent/ES2278020T3/es not_active Expired - Lifetime
- 2002-02-01 JP JP2002564956A patent/JP4489352B2/ja not_active Expired - Fee Related
- 2002-02-01 DK DK02724908T patent/DK1358209T3/da active
- 2002-02-01 CA CA002431033A patent/CA2431033A1/en not_active Abandoned
- 2002-02-01 IL IL15643502A patent/IL156435A0/xx unknown
- 2002-02-01 WO PCT/US2002/003156 patent/WO2002064627A2/en not_active Ceased
- 2002-02-01 BR BR0207422-2A patent/BR0207422A/pt not_active Application Discontinuation
- 2002-02-01 EP EP06026833A patent/EP1801120A1/en not_active Withdrawn
- 2002-02-01 DE DE60217066T patent/DE60217066T4/de not_active Expired - Lifetime
- 2002-02-01 AU AU2002255508A patent/AU2002255508B2/en not_active Ceased
- 2002-02-01 EP EP06026832A patent/EP1772464B1/en not_active Expired - Lifetime
- 2002-02-01 AT AT02724908T patent/ATE349469T1/de active
- 2002-02-01 EP EP02724908A patent/EP1358209B1/en not_active Expired - Lifetime
- 2002-02-01 NZ NZ548359A patent/NZ548359A/en not_active IP Right Cessation
- 2002-02-01 CN CNB028047079A patent/CN100439397C/zh not_active Expired - Fee Related
- 2002-02-01 US US10/066,009 patent/US7084240B2/en not_active Expired - Fee Related
- 2002-02-01 ES ES06026832T patent/ES2331150T3/es not_active Expired - Lifetime
- 2002-02-01 DE DE60233359T patent/DE60233359D1/de not_active Expired - Lifetime
- 2002-02-01 KR KR1020037010465A patent/KR100872613B1/ko not_active Expired - Fee Related
- 2002-02-01 NZ NZ548358A patent/NZ548358A/en not_active IP Right Cessation
-
2003
- 2003-06-12 IL IL156435A patent/IL156435A/en not_active IP Right Cessation
- 2003-06-24 ZA ZA2003/04900A patent/ZA200304900B/en unknown
-
2005
- 2005-04-14 US US11/107,672 patent/US7238658B2/en not_active Expired - Fee Related
-
2006
- 2006-06-20 US US11/471,897 patent/US7433788B2/en not_active Expired - Fee Related
- 2006-06-20 US US11/472,121 patent/US7354769B2/en not_active Expired - Fee Related
- 2006-06-20 US US11/471,896 patent/US7596455B2/en not_active Expired - Fee Related
- 2006-06-20 US US11/472,122 patent/US20060270839A1/en not_active Abandoned
- 2006-06-20 US US11/471,895 patent/US20060276397A1/en not_active Abandoned
- 2006-06-20 US US11/471,912 patent/US7297763B2/en not_active Expired - Fee Related
-
2009
- 2009-04-06 JP JP2009092074A patent/JP2009215299A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009215299A5 (enExample) | ||
| CN103180734B (zh) | 稳定gpcr的功能构象状态的蛋白结合结构域及其用途 | |
| KR100872613B1 (ko) | Ｉｇｆ-1의 결정화 | |
| US8507209B2 (en) | Biomarkers | |
| US20090117662A1 (en) | Mutants of IGF Binding Proteins and Methods of Production of Antagonists Thereof | |
| AU2002255508A1 (en) | Crystallization of IGF-1 | |
| CN107043418A (zh) | 生物标记物 | |
| JP2006525782A5 (enExample) | ||
| Denley et al. | Structural and functional characteristics of the Val44Met IGF-I missense mutation: correlation with effects on growth and development | |
| JP2006526384A5 (enExample) | ||
| HK1060138B (en) | Crystallization of igf-1 |